BioLargo Inc (OTCMKTS:BLGO), CEO Dennis Calvert, pitches to investors at the Proactive One2One Virtual Forum. The innovative technology developer and environmental engineering company is driven by a mission to 'make life better', by delivering robust, sustainable solutions for a broad range of industries and applications.
BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact.
Thursday, 28 January 2021
Dennis Calvert Shared BioLargo's 2020 Accomplishments and What's to Come in a Proactive One2One Live Virtual Forum
BioLargo Inc (OTCMKTS:BLGO), CEO Dennis Calvert, pitches to investors at the Proactive One2One Virtual Forum. The innovative technology developer and environmental engineering company is driven by a mission to 'make life better', by delivering robust, sustainable solutions for a broad range of industries and applications.
Tuesday, 26 January 2021
BioLargo's AEC Removal of Forever Chemicals PFAS is Confirmed 99.995% Effective in Lab Analysis Performed at the University of Tennessee
AEC Features Dramatic Reduction in Carbon Footprint Associated with Disposal
WESTMINSTER, CA / January 26, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable
technologies and a full-service environmental engineering company, today announced
new testing on its AEC water technology system, which has been
proven to remove 99.9% of PFAS (so called "forever chemicals") from
water in a single pass. PFAS chemicals are a new focus of the Biden Administration,
who's nominee for EPA Administrator, Michael Regan, is being heralded by
environmental groups for his work combatting PFAS contamination
in North Carolina.
PFAS are a class of
man-made chemical contaminants that are bioaccumulative and are associated with
a host of serious health problems. Last week the US EPA announced it
had issued "final regulatory determinations" to that will officially
regulate safe levels of PFAS chemicals in drinking water.
Testing at the
University of Tennessee in Knoxville showed that PFAS compounds are attracted
and bound to the surface of the AEC's proprietary membranes, which in a single
pass collect over 99.995%, such that less than one out of 50,000 PFAS molecules
was able to penetrate the membrane.
Randall Moore,
President of BioLargo Engineering commented, "This study confirms that the
AEC is effective to selectively extract PFAS from water in an extraordinarily
cost-effective way. Competing technologies reliant on carbon media create a
significant amount of carbon waste that is often incinerated, releasing
greenhouse gas emissions. This new study confirms the AEC reduces the waste
produced to a fraction of the competition - imagine that to treat the same
volume of water, while carbon solutions will create a truckload of spent carbon
for disposal, our AEC system will create a waste product the size of a brief
case."
Dennis P. Calvert, CEO
at BioLargo commented, "With the recent EPA action and Biden
Administration's focus on these ‘forever chemicals,' our AEC technology is in a
position to become an industry standard. Thankfully, our team recognized the
need for efficient removal for PFAS early and has invested the last two years
developing the AEC to a now ready for commercialization stage. We are preparing
for commercial trials as soon as possible and have a number of municipal water
agencies that want to work with us. We expect to share more information about
our AEC as it progresses."
About BioLargo, Inc.
BioLargo, Inc.
(OTCQB:BLGO) invents, develops, and commercializes innovative platform
technologies to solve challenging environmental problems like PFAS
contamination, advanced water and wastewater treatment, industrial odor and VOC
control, air quality control, and infection control. With over 13 years of
extensive R&D, BLGO holds a wide array of issued patents, maintains a
robust pipeline of products, and provides full-service environmental
engineering. Our peer-reviewed scientific approach allows us to invent or
acquire novel technologies and develop them to maturity through our operating
subsidiaries. With a keen emphasis on collaborations with academic, municipal,
and commercial organizations and associations, BLGO has proven itself with over
80 awarded grants and numerous pilot projects. We monetize through direct
sales, recurring service contracts, licensing agreements, strategic joint
venture formation and/or the sale of the IP. Several of our technologies are
commercially available and are advancing as disrupters in their respective
markets. See our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act -
caution regarding forward looking statements
This press release
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements
include without limitation those about BioLargo's (the "Company")
expectations regarding the impact of the COVID-19 pandemic; anticipated
revenue; and plans for future operations. These statements involve risks and
uncertainties, and actual results may differ materially from any future results
expressed or implied by the forward-looking statements. Risks and uncertainties
include without limitation: the effect of the COVID-19 pandemic on the
Company's business, results of operations, financial condition, and stock
price; the effect of regional economic conditions on the Company's business,
including effects on purchasing decisions by consumers and businesses; the
ability of the Company to compete in markets that are highly competitive and
subject to rapid technological change; the ability of the Company to manage
frequent introductions and transitions of products and services, including
delivering to the marketplace, and stimulating customer demand for, new
products, services, and technological innovations on a timely basis; the
dependency of the Company on the performance of distributors of the Company's
products. More information on these risks and other potential factors that
could affect the Company's business and financial results is included in the
Company's filings with the SEC, including in the "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and Results
of Operations" sections of the Company's most recently filed periodic
reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes
no obligation to update any forward-looking statements or information, which
speak as of their respective dates.
Monday, 25 January 2021
BioLargo Generates Record Revenue in 2020
President and CEO Dennis P. Calvert to highlight significant growth opportunities at upcoming investor conference this Tuesday, January 26th, 2021
WESTMINSTER, CA /
ACCESSWIRE / January 25, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable
technologies and a full-service environmental engineering company, today
announced record annual revenues in 2020 and record quarterly revenues in the
fourth quarter of 2020. BioLargo President and CEO Dennis P. Calvert will be
discussing how the company intends to capitalize on recent growth by executing
new product launches in 2021 in his upcoming investor presentation on January
26, 2021 (details below).
In the year ended
December 31, 2020, BioLargo generated approximately $2.4 million in revenue, a
31% increase compared to the previous year. In the quarter ended December 31,
2020, BioLargo generated approximately $900,000 in company-wide revenue, a 36%
increase compared to the prior quarter. (These results are not yet audited.)
In addition to setting
revenue records, during 2020 BioLargo also reduced its debt obligations by
converting approximately $3.7 million in notes payable to equity.
BioLargo President and
CEO Dennis P. Calvert commented, "2020 was a great year of important
accomplishments - increased revenue, product breakthroughs and reduction of
debt to manageable levels. We fully expect that revenue will continue growing,
and we will continue concentrating on improving our balance sheet. Of our remaining
debt, over $1 million is owed solely by Clyra Medical, over $500,000 is SBA
loans, some of which will be forgiven, and $1.1 million may be converted to
equity by the investors."
Dennis will be
discussing the company's recent growth and its plans to accelerate its revenues
with new water technology product launches in an investor presentation hosted
by Proactive Investors on January 26, 2021. BioLargo's presentation is in the
10:00 AM PST / 1:00 PM EST time slot. Highlights will include the commercial
pilot project where the AOS water treatment system will turn poultry processing
wastewater into reusable water, the municipal wastewater treatment pilot
featuring the AOS and BioLargo's new water technology, the AEC, which can
effectively remove PFAS chemicals from water, and the progress on the company's
operational subsidiaries efforts at profitability.
Registration for the
event (free) can be done here: https://www.proactiveinvestors.com/register/event_details/316
About BioLargo, Inc.
BioLargo, Inc.
(OTCQB:BLGO) invents, develops, and commercializes innovative platform
technologies to solve challenging environmental problems like PFAS
contamination, advanced water and wastewater treatment, industrial odor and VOC
control, air quality control, and infection control. With over 13 years of
extensive R&D, BLGO holds a wide array of issued patents, maintains a
robust pipeline of products, and provides full-service environmental
engineering. Our peer-reviewed scientific approach allows us to invent or
acquire novel technologies and develop them to maturity through our operating
subsidiaries. With a keen emphasis on collaborations with academic, municipal,
and commercial organizations and associations, BLGO has proven itself with over
80 awarded grants and numerous pilot projects. We monetize through direct
sales, recurring service contracts, licensing agreements, strategic joint
venture formation and/or the sale of the IP. Several of our technologies are
commercially available and are advancing as disrupters in their respective
markets. See our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act -
caution regarding forward looking statements
This press release
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements
include without limitation those about BioLargo's (the "Company")
expectations regarding the impact of the COVID-19 pandemic; anticipated
revenue; and plans for future operations. These statements involve risks and
uncertainties, and actual results may differ materially from any future results
expressed or implied by the forward-looking statements. Risks and uncertainties
include without limitation: the effect of the COVID-19 pandemic on the
Company's business, results of operations, financial condition, and stock
price; the effect of regional economic conditions on the Company's business,
including effects on purchasing decisions by consumers and businesses; the
ability of the Company to compete in markets that are highly competitive and
subject to rapid technological change; the ability of the Company to manage
frequent introductions and transitions of products and services, including
delivering to the marketplace, and stimulating customer demand for, new
products, services, and technological innovations on a timely basis; the dependency
of the Company on the performance of distributors of the Company's products.
More information on these risks and other potential factors that could affect
the Company's business and financial results is included in the Company's
filings with the SEC, including in the "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and Results
of Operations" sections of the Company's most recently filed periodic
reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no
obligation to update any forward-looking statements or information, which speak
as of their respective dates.
Tuesday, 19 January 2021
BioLargo Completes Manufacture of First Commercial-Scale AOS Unit for Municipal Wastewater Treatment Plant
Westminster, CA – January 19, 2021 – BioLargo, Inc. (OTCQB:BLGO), developer of cutting-edge environmental technologies and a full-service engineering company, announced today that it has completed manufacturing of its first-ever commercial-scale AOS water treatment unit, which will be shipped to a municipal wastewater treatment plant near Montréal, Québec for a pilot project. The pilot is to be run independently by water treatment technology experts from the world-renowned Centre des Technologies de l’Eau (CTE) in Montreal and will provide real-time data of AOS performance in a municipal wastewater stream. Pictures of the commercial AOS unit are provided below.
The unit being shipped can treat up to 100 gallons per
minute of municipal wastewater, and will eliminate bacteria, viruses, and other
organisms. As a modular design, it can easily be scaled up by adding modules to
treat whatever volumes are needed to manage required wastewater streams for the
customer. Unlike other wastewater disinfection systems, the AOS has been shown
to remove micropollutants (including, but not limited to estradiol, benzo[a]pyrene,
ibuprofen, and amoxicillin) from the wastewater. The unit comes complete with
industrial controls, sensors, and is designed to operate in the field for
extended periods without supervision.
A photo gallery of the commercial-scale AOS unit can be found
on the company’s blog here: https://www.biolargo.com/case-studies
The pilot project will provide crucial field validation data for the municipal wastewater market and will highlight the value proposition of the AOS – high performance, able to remove hard-to-remove micropollutants, and low operating costs, including the consumption of less electrical energy than competing technologies. Later this year, BioLargo intends to add its AEC technology, which removes per- and poly-fluoroalkyl substances (PFAS) from water more affordably while producing less waste than other technologies, to the pilot project. More information about the pilot can be found in the company’s previous press release which announced the pilot: https://biolargo.blogspot.com/2020/08/biolargo-announces-municipal-wastewater.html.
BioLargo President & CEO Dennis P. Calvert commented, “This
is a critical moment for the commercialization of the AOS. We are delivering a
full commercial-scale AOS unit, robust enough to handle high volumes of water
over an extended period of time, and which includes all the controls required
for a commercial unit. This pilot showcases the AOS and provides future
customers with a success story that helps them recognize the extraordinary
performance, micropollutant removal, and cost- and energy-efficiency of the AOS.”
About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products
and environmental engineering solutions provider driven by a mission to “make
life better”. We feature unique
disruptive solutions to deliver clean air, clean water and a clean, safe
environment (www.biolargo.com). Our
engineering division features experienced professional engineers dedicated to
integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our
industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features
CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com),
which eliminates the odor-causing compounds and VOCs rather than masking them,
and is now winning over leading companies in the solid waste handling and
wastewater industries and other industries that contend with malodors and VOCs.
Our subsidiary BioLargo Water (www.biolargowater.ca)
develops the Advanced Oxidation System "AOS," a disruptive industrial
water treatment technology designed to eliminate waterborne pathogens and
recalcitrant contaminants with better energy-efficiency and lower operational
costs than incumbent technologies. We are a minority stockholder of and
technology licensor to our subsidiary Clyra Medical which features its
breakthrough product Clyraguard (www.clyramedical.com/clyraguard),
an FDA Registered, hospital grade disinfectant for personal protective
equipment including facemasks, proven 99.999% effective and safe for skin, as
well as its other products offering gentle solutions for chronic infected
wounds to promote infection control and regenerative tissue therapy.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
During the course of the stockholder
presentation, BioLargo may make “forward-looking statements” within the meaning
of the safe harbor provisions of the United States Private Securities
Litigation Reform Act of 1995, regarding future events or the future financial
performance of the company that are subject to change. Actual results may
differ from expectations, estimates and projections and, consequently, you
should not rely on these forward-looking statements as predictions of future
events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,”
“predicts,” “potential,” “continue,” and similar expressions are intended to
identify such forward-looking statements. These forward-looking statements involve
significant risks and uncertainties that could cause the actual results to
differ materially from the expected results.
Wednesday, 6 January 2021
BioLargo Discusses 2021 Goals for Growth with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - January 6, 2021) - The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO), developer of cutting-edge environmental technologies and a full-service engineering company for an interview. President and CEO of BioLargo, Dennis P. Calvert, joined Stock Day host Everett Jolly.
Jolly began the interview by asking about the publication of a recent peer-reviewed paper about BioLargo's AOS water treatment system. "This is a really special asset…It represents a technical breakthrough in efficiency for high level disinfection and for extracting what the industry calls micropollutants," said Calvert, noting "that's an area of increasing concern by regulators," some of which are regulated already.
"This innovation that we have created has gone through a full development cycle. It is a state-of-the-art technical breakthrough in [water treatment] efficiency," said Calvert, before elaborating on the value of the positive confirmations shown in the peer-reviewed paper. "This is a credentialing stamp," he explained, adding that the paper has proven that the AOS is effective, efficient, and safe, and that scalable AOS models are now being manufactured. "In any given moment, about a third of the market could use this innovation in their system," Calvert says.
"We've got our first customer. It's a project [for the AOS] worth about half a million dollars in total," shared Calvert. "The future is really bright for the asset. Now we're in the process of interviewing distributors, [developing] our first customers, and we think the future of our water innovation is really pretty exciting."
Jolly commented on BioLargo's record revenues and asked about the potential of the first three quarters of 2021. Calvert started by describing the growth its air quality control division, ONM Environmental, is experiencing. "We're finding ourselves with showcase accounts that are becoming increasingly large. It's a testimony to the science, it's a testimony to the innovation of creating this [odor and VOC control product] delivery model," said Calvert, adding that the Company has built up a backlog of work in their other divisions.
"We're having organic real-time growth," shared Calvert. "We've also got our PFAS solution coming to market in 2021 for commercial trials," shared Calvert, noting the huge size and value of PFAS water treatment markets.
Calvert shared that BioLargo is on track to hit a new record for annual revenue for 2020. "The rate of growth is a record," added Calvert. "The engineers are entering into the quarter with $1.6 million in backlog," said Calvert, and "the ONM operation has approximately a quarter of a million in backlog," he continued.
"How far away are we from positive cash flow, and how are we going to maintain operations until we get to that point?" asked Jolly. Calvert explained, "We want to raise the capital only necessary to get through that gap and then expand with a proven track record for growth capital to really accelerate the growth and start driving profits and revenues for our shareholders," explained Calvert, before elaborating on the Company's robust portfolio. "What we're focused on as a company is just getting it done."
"First thing's first, let's get ourselves to break even, chart the course, and really start generating the kind of cash and profits that our shareholders want, need, and deserve, and we think that's much closer in hand than you might think," closed Calvert.
To hear the entire interview, follow the link to the podcast here: https://audioboom.com/posts/7765702-biolargo-discusses-2021-goals-for-growth-with-the-stock-day-podcast
Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/
About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to "make life better". We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) developed the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard (www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.
About The "Stock Day" Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.
SOURCE:
Stock Day Media
(602) 821-1102
Monday, 4 January 2021
Peer-Reviewed Paper Confirms BioLargo’s Advanced Oxidation System Safely Removes Micropollutants from Wastewater
Westminster, CA – January 4, 2021 – BioLargo, Inc. (OTCQB:BLGO), developer of cutting-edge environmental technologies and a full-service engineering company, announced the publication of a peer-reviewed scientific paper in the Journal of Environmental Management confirming that the energy-efficient and cost-effective Advanced Oxidation System (AOS) water disinfection system also safely removes certain micropollutants from municipal wastewater. The paper concludes that the AOS is “a promising and environmentally friendly technology for wastewater treatment, remediation, and management”, highlighting the additional value the AOS can provide customers by addressing an important and poorly served technical need in the water industry. Dr. Greg Goss, in the Faculty of Science at the University of Alberta and the researcher who led the study, commented “The AOS is a major technological breakthrough for the treatment of micropollutants.”
Micropollutants are widespread synthetic chemicals that end up in municipal water supplies around the world. They originate from pharmaceuticals, personal care products, detergents, pesticides and more, and are linked to ecological damage and human health issues. They are distinct from other water contaminants because they are difficult and expensive to remove using conventional technologies such as UV, ozone, and biological treatment.
The need for cost-effective treatment of micropollutants in water and wastewater is well recognized in the water industry. One significant issue with municipal wastewater is the feminization of fish in the receiving environment due the presence of endocrine disrupting chemicals (EDC) such as estradiol. This paper reports that the BioLargo AOS effectively removes the EDC effects of estradiol commonly present in municipal wastewater. The other micropollutant tested in the study, benzo[a]pyrene, is regulated by the EPA pursuant to the Safe Water Drinking Act. The U.S. EPA maintains a published list of “contaminants of emerging concern” that includes a number of additional micropollutants in municipal wastewater that may cause ecological or human health impacts, but are not yet regulated. As regulatory scrutiny continues to increase surrounding micropollutants, municipalities are seeking technologies that can affordably and safely remove them from their wastewater streams to prevent surface water contamination.
BioLargo’s ground-breaking and patented Advanced Oxidation System (AOS) is a water treatment platform that provides high-level disinfection and consumes less electricity than competing technologies. The AOS’ ability to eliminate the deleterious effects of micropollutants in wastewater offers significant additional value to the municipal wastewater treatment market by providing affordable and effective micropollutant removal in addition to its primary use as an energy-efficient and cost-effective wastewater disinfection technology.
Two
significant commercial-scale AOS projects are starting in the coming year. The
first, at a municipal wastewater treatment plant near Montreal, Canada, will
assess the AOS’ ability to efficiently disinfect and remove micropollutants and
other organic contaminants at an operating municipal wastewater treatment plant.
The second will treat poultry-processing wastewater at a certified organic farm
in Alberta, Canada. The development of the AOS, and both pilot projects, are being
led by BioLargo’s Alberta, Canada, based subsidiary, BioLargo Water. In
addition to these two commercial-scale pilot projects, BioLargo is now
screening potential distributors in North America.
Dr. Richard Smith, President of BioLargo Water, commented, “We
will be shipping our first commercial-scale AOS unit in the coming weeks to the
wastewater treatment plant near Montreal, and will install our first full-scale
‘zero liquid discharge’ system in our project with Sunworks Farms in Alberta in
the first half of 2021. These initial projects will help demonstrate the
substantial value the AOS provides in wastewater treatment, and we believe will
ultimately lead to significant market adoption.”
To read the peer-reviewed published paper, visit: https://authors.elsevier.com/a/1cHo114Z6telDf
Highlights from
the paper:
- AOS is highly effective at eliminating the negative effects of two particularly difficult micropollutants, suggesting it may be effective against a wide range of similar compounds.
- The AOS requires extremely low levels of electric energy to operate.
- The AOS did not increase toxicity or introduce additional hazards (i.e., decontamination by-products) in the post-treatment effluent.
This work was funded in part by the Canadian Natural Science
and Engineering Research Council (NSERC) and the National Research Council of
Canada Industrial Research Assistance Program (NRC IRAP).
To learn more about BioLargo Water and the AOS, visit www.biolargowater.com
and the website of its parent company BioLargo at www.biolargo.com.
About BioLargo, Inc.
BioLargo, Inc. is an innovator of technology-based products and
environmental engineering solutions provider driven by a mission to “make life
better”. We feature unique disruptive
solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our
engineering division features experienced professional engineers dedicated to
integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our
industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features
CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which
eliminates the odor-causing compounds and VOCs rather than masking them, and is
now winning over leading companies in the solid waste handling and wastewater
industries and other industries that contend with malodors and VOCs. Our
subsidiary BioLargo Water (www.biolargowater.ca) developed
the Advanced Oxidation System "AOS," a disruptive industrial water
treatment technology designed to eliminate waterborne pathogens and
recalcitrant contaminants with better energy-efficiency and lower operational
costs than incumbent technologies. We are a minority stockholder of and
technology licensor to our subsidiary Clyra Medical which features its
breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA
Registered, hospital grade disinfectant for personal protective equipment
including facemasks, proven 99.999% effective and safe for skin, as well as its
other products offering gentle solutions for chronic infected wounds to promote
infection control and regenerative tissue therapy.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include without limitation those
about BioLargo’s (the “Company”) expectations regarding the impact of the
COVID-19 pandemic; anticipated revenue; and plans for future operations. These
statements involve risks and uncertainties, and actual results may differ
materially from any future results expressed or implied by the forward-looking
statements. Risks and uncertainties include without limitation: the effect of
the COVID-19 pandemic on the Company’s business, results of operations,
financial condition, and stock price; the effect of regional economic
conditions on the Company’s business, including effects on purchasing decisions
by consumers and businesses; the ability of the Company to compete in markets
that are highly competitive and subject to rapid technological change; the
ability of the Company to manage frequent introductions and transitions of
products and services, including delivering to the marketplace, and stimulating
customer demand for, new products, services, and technological innovations on a
timely basis; the dependency of the Company on the performance of distributors
of the Company’s products. More information on these risks and other potential
factors that could affect the Company’s business and financial results is
included in the Company’s filings with the SEC, including in the “Risk Factors”
and “Management’s Discussion and Analysis of Financial Condition and Results of
Operations” sections of the Company’s most recently filed periodic reports on
Form 10-K and Form 10-Q and subsequent filings. The Company assumes no
obligation to update any forward-looking statements or information, which speak
as of their respective dates.